Ignite Creation Date:
2025-12-24 @ 10:20 PM
Ignite Modification Date:
2026-01-22 @ 9:49 AM
Study NCT ID:
NCT05025735
Status:
UNKNOWN
Last Update Posted:
2021-10-19
First Post:
2021-06-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
Sponsor:
Saint Luke's Health System
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CBYL719A0US03T
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |